Author response: Knowledge synthesis of 100 million biomedical documents augments the deep expression profiling of coronavirus receptors

Venkatakrishnan, AJ; Puranik, Arjun; Anand, Akash; Zemmour, David; Yao, Xiang; Wu, Xiaoying; Chilaka, Ramakrishna; Murakowski, Dariusz K.; Standish, Kristopher; Raghunathan, Bharathwaj; Wagner, Tyler; Garcia-Rivera, Enrique; Solomon, Hugo; Garg, Abhinav; Barve, Rakesh; Anyanwu-Ofili, Anuli; Khan, Najat; Soundararajan, Venky

doi:10.7554/elife.58040.sa2

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SARS-CoV-2 RNA may continue to be detectable in fecal samples from patients with a negative nasal-oropharyngeal swab and is associated with a longer interval from symptom onset to viral clearance (14,(16)(17)(18). Angiotensin-converting enzyme 2, which acts as a host receptor protein to bind coronavirus spikes and enable subsequent viral-host cell membrane fusion and viral entry, is expressed relatively strongly by intestinal epithelial cells (19)(20)(21)(22). Future research should investigate a possible association of fecal SARS-CoV-2 RNA with persistent COVID-19 diseaserelated symptoms.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19

Alper

2020

Front. Med.

View full text Add to dashboard Cite

Famotidine is of interest as a possible treatment for COVID-19, with effects on disease-related symptoms and survival reported in observational and retrospective studies, as well as in silico predictions of binding to potential SARS-CoV-2 drug targets. Published studies of famotidine for COVID-19 have focused on acute illness, and none have reported on neuropsychiatric symptoms. This case study reports on an 18-year-old man who sought psychiatric treatment for depression and anxiety, disruptive interpersonal conflicts, and impairments in attention and motivation following mildly symptomatic illness with COVID-19. The neuropsychiatric symptoms, which had been present for 16 weeks at the time of the initial evaluation represented a significant departure from the patient's previous behavioral baseline. The patient had no prior psychiatric history preceding his illness with COVID-19, and no history of any prior treatment with psychopharmacological medications. Famotidine 20 mg twice daily administered orally was begun without any additional medications. At 1-week follow-up the patient was much improved. Improvement was sustained through 12 weeks of follow-up during which the patient continued to take famotidine without apparent side effects. With progression of the COVID-19 pandemic it has become evident that persistent disease-related symptoms may follow acute COVID-19 and may include neuropsychiatric symptoms. Controlled clinical research on famotidine for COVID-19 should follow, as well as the development of valid and reliable research diagnostic criteria to define and operationalize the features of a putative COVID-19 neuropsychiatric residual.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Famotidine for Neuropsychiatric Symptoms in COVID-19

Alper

2020

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Angiotensin converting enzyme 2 (ACE2) is a functional receptor of SARS-CoV ( 27), SARS-CoV-2 (28), and SARS-CoV-2-related pangolin coronavirus (GX_P2V) (29). SARS-CoV-2 viral RNA could not be detected in most breast milk samples of infected mothers, which may be possibly due to low levels of ACE2 expression in the breasts (30)(31)(32). ACE2 expression in the female reproductive system, including the mammary glands, is extremely low, suggesting a low possibility of high levels of infectious SARS-CoV-2 in breast milk (10).…”

Section: The Expression Level Of Angiotensin Converting Enzyme 2 In Mammary Epithelial Cells Is Extremely Lowmentioning

confidence: 99%